May 15, 2021
  • May 15, 2021
  • Home
  • Lifestyle
  • Health ministry decides against including Itolizumab in clinical management protocols for coronavirus

Health ministry decides against including Itolizumab in clinical management protocols for coronavirus

By on July 27, 2020 0 106 Views

The National Task Force on Covid-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease. The issue of including the drug in the clinical protocols was discussed in a meeting held on Friday.

The National Task Force on Covid-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its “restricted emergency use” in infected patients, official sources said.

Considering the unmet medical needs in Covid-19, Itolizumab, an already approved drug of Biocon, used for treating psoriasis – a skin condition – was approved for “restricted emergency use” in the treatment of coronavirus by the Drugs Controller General of India (DCGI) recently.

The permission to market the drug was granted for the treatment of cytokine release syndrome in ‘moderate’ to ‘severe’ Acute Respiratory Distress Syndrome patients due to Covid-19.

“The issue of including the drug in the clinical protocols was discussed in a meeting held on Friday. A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for Covid-19,” said an official source.

ReadMore…